<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Tuberculosis disease (active tuberculosis) in pregnancy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Tuberculosis disease (active tuberculosis) in pregnancy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Tuberculosis disease (active tuberculosis) in pregnancy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lloyd N Friedman, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lynn T Tanoue, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            C Fordham von Reyn, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Charles J Lockwood, MD, MHCM
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elinor L Baron, MD, DTMH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 01, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tuberculosis (TB) terminology is inconsistent in the literature  (
         <a class="graphic graphic_table graphicRef132526" href="/z/d/graphic/132526.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. The following terms are used in this discussion:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tuberculosis infection (newer term for latent tuberculosis)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tuberculosis disease (newer term for active tuberculosis)
        </p>
        <p>
        </p>
        <p>
         Prenatal care presents a unique opportunity for evaluation and management of TB infection and TB disease among individuals with risk of TB who may not otherwise present for medical care.
        </p>
        <p>
         Organizations with published guidance for management of TB include the United States Centers for Disease Control and Prevention (CDC), the United States National Tuberculosis Controllers Association (NTCA), the United States Department of Health and Human Services (DHHS), the American Thoracic Society (ATS), the Infectious Disease Society of America (IDSA), and the World Health Organization (WHO) [
         <a href="#rid2">
          2-7
         </a>
         ].
        </p>
        <p>
         Issues related to diagnosis and treatment of TB disease in pregnant patients will be reviewed here, for TB that is presumed or demonstrated to be susceptible to
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         and/or
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         .
        </p>
        <p>
         Issues related to diagnosis and treatment of TB infection in pregnant patients are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/135001.html" rel="external">
          "Tuberculosis infection (latent tuberculosis) in pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H848454351">
         <span class="h1">
          TERMINOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tuberculosis terminology is inconsistent in the literature [
         <a href="#rid1">
          1
         </a>
         ]. Relevant terms are defined in the table  (
         <a class="graphic graphic_table graphicRef132526" href="/z/d/graphic/132526.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H4159545334">
         <span class="h1">
          NATURAL HISTORY OF TB IN PREGNANCY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tuberculosis infection is caused by inhalation of viable bacilli, which may persist in a clinically inactive state (known as TB infection [TBI]) or progress to TB disease.
        </p>
        <p>
         Individuals with TBI are asymptomatic and not contagious. Latent TB bacilli remain viable and may reactivate, causing symptomatic TB disease, which can be transmitted via airborne spread.
        </p>
        <p>
         Postpartum patients with TB disease can transmit infection to their infants; this is discussed further below. (See
         <a class="local">
          'Controlling transmission'
         </a>
         below.)
        </p>
        <p>
         Maternal TB disease may be associated with congenital infection by hematogenous dissemination via the placenta; this is very rare. (See
         <a class="medical medical_review" href="/z/d/html/8007.html" rel="external">
          "Tuberculosis disease in children: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pregnant patients with pulmonary TB have the same clinical manifestations as nonpregnant patients; these may include fever, cough, weight loss, night sweats, and malaise. Pulmonary TB disease may be transmitted via airborne spread.
        </p>
        <p>
         TB in pregnant patients can present insidiously since malaise and fatigue may be attributed to pregnancy rather than disease [
         <a href="#rid8">
          8-13
         </a>
         ]. In addition, during pregnancy, it can be difficult to recognize weight loss. (See
         <a class="medical medical_review" href="/z/d/html/7026.html" rel="external">
          "Pulmonary tuberculosis: Clinical manifestations and complications"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnostic evaluation for TB disease is warranted in the setting of clinical suspicion for TB disease, based on clinical manifestations and epidemiologic factors (such as exposure to a known or suspected case, residence in or travel to an endemic area).
        </p>
        <p>
         The approach to diagnosis for TB disease in pregnant patients is the same as in nonpregnant individuals; it consists of clinical history (including epidemiologic assessment) and physical examination followed by chest radiography (with appropriate shielding to protect the fetus) [
         <a href="#rid14">
          14
         </a>
         ]. Chest imaging suggestive of pulmonary TB should prompt submission of three sputum specimens (coughed or induced) for acid-fast bacilli smear and culture as well as at least one sputum specimen for
         <em>
          Mycobacterium tuberculosis
         </em>
         nucleic acid amplification testing. (See
         <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">
          "Diagnosis of pulmonary tuberculosis in adults"
         </a>
         .)
        </p>
        <p>
         A positive
         <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">
          tuberculin skin test
         </a>
         (TST) or interferon-gamma release assay (IGRA) supports a diagnosis of TB infection but, in the absence of other evidence, is not sufficient for diagnosis of TB disease. In addition, a negative TST or IGRA result does not rule out TB disease.
        </p>
        <p>
         Diagnosis of TB disease should prompt evaluation for HIV infection. (See
         <a class="medical medical_review" href="/z/d/html/3736.html" rel="external">
          "Screening and diagnostic testing for HIV infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H3099895273">
         <span class="h2">
          Whom to treat
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of TB in the setting of pregnancy should be initiated if the suspicion of TB disease is moderate to high (such as a positive sputum acid-fast bacilli smear, positive sputum nucleic acid amplification test, or cough and upper lobe infiltrate in an individual with relevant risk factors). (See
         <a class="medical medical_review" href="/z/d/html/8018.html" rel="external">
          "Epidemiology of tuberculosis", section on 'Risk factors'
         </a>
         .)
        </p>
        <p>
         TB disease in pregnancy is associated with adverse maternal and fetal outcomes; untreated TB disease represents a greater hazard to the mother and fetus than antituberculous therapy [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         Other principles for treatment of TB disease in pregnant patients are the same as for nonpregnant patients. (See
         <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1598904770">
         <span class="h2">
          Clinical approach
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial treatment regimen
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients without HIV infection
         </strong>
         – The regimen for empiric treatment of presumed drug-susceptible TB disease during pregnancy in the United States consists of
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         administered for two months, followed by isoniazid and rifampin for seven months, for a total of nine months of treatment [
         <a href="#rid5">
          5,16-18
         </a>
         ]. If the results of drug susceptibility studies are available and the isolate is known to be susceptible to isoniazid and rifampin, ethambutol may be discontinued after one month.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          Pyrazinamide
         </a>
         is not absolutely necessary as part of a first-line regimen for TB disease. Detailed teratogenicity data are not available for this agent, so it is often excluded from TB treatment for pregnant patients in the United States; some favor its use for patients with severe and/or extrapulmonary TB [
         <a href="#rid5">
          5,19
         </a>
         ]. In contrast with United States practice, pyrazinamide is recommended by the World Health Organization as part of a standard regimen for treatment of TB in pregnant patients [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         If a decision is made to include
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         , the treatment duration can be shortened from nine months to six months in most patients [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The rifapentine-moxifloxacin-based four-month regimen has not been studied in pregnant patients and should not be used in this population [
         <a href="#rid21">
          21,22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients with HIV infection
         </strong>
         – In general, the approach to antituberculous therapy for pregnant patients with HIV infection is the same as for pregnant patients without HIV infection. However, careful attention to drug interactions is critical. For patients on rifampin-based TB treatment, only a limited number of antiretroviral medications within a limited number of drug classes can be coadministered, due to drug interactions that adversely affect HIV treatment efficacy. Such cases should be managed in consultation with an expert in TB and HIV drug interactions. (See
         <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy", section on 'Drug interactions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug dosing
         </strong>
         – Dosing regimens for treatment of TB are summarized separately. (See
         <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tailoring treatment
         </strong>
         – Drug susceptibility data should be reviewed when available, and treatment should be adjusted if needed. Issues related to treatment of drug-resistant TB in pregnancy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8028.html" rel="external">
          "Treatment of drug-resistant pulmonary tuberculosis in adults", section on 'Pregnant patients'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Directly observed therapy
         </strong>
         – Treatment should be administered by directly observed therapy using patient-centered case management wherever possible. (See
         <a class="medical medical_review" href="/z/d/html/8019.html" rel="external">
          "Adherence to tuberculosis treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment interruptions
         </strong>
         – Treatment interruptions longer than two weeks, suspected or confirmed drug resistance, or sporadic adherence should prompt consultation with an expert in tuberculosis. Nonadherence within the first two months of treatment generally warrants restarting treatment from the beginning [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         –
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          Isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         are generally considered by experts to be acceptable for use in pregnancy [
         <a href="#rid5">
          5,23,24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Isoniazid
         </strong>
         – Use of
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         may be associated with increased risk of hepatitis and peripheral neurotoxicity in the peripartum period, especially in Hispanic or African American individuals [
         <a href="#rid5">
          5,10,18,23-27
         </a>
         ]. In general, the benefit of isoniazid (given its importance for treatment of TB disease) justifies the potential risk.
         <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">
          Pyridoxine
         </a>
         should be administered to pregnant patients receiving isoniazid and to their breastfeeding infants (even if the infant is not receiving isoniazid therapy) [
         <a href="#rid5">
          5,28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Other side effects of
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         include rashes, neuropsychiatric disturbances including depression, mania, memory loss and/or psychosis, pellagra, peripheral neuritis, and seizures.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Rifamycins
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Adverse effects
         </strong>
         – Adverse effects due to
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         include hepatitis, thrombocytopenia, hemolytic anemia, fever, and rash. Use of rifampin also has been associated with rare cases of fetal abnormalities and hemorrhagic disease [
         <a href="#rid5">
          5,23,28,29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/491.html" rel="external">
          "Rifamycins (rifampin, rifabutin, rifapentine)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Nitrosamine impurities
         </strong>
         – The US Food and Drug Administration (FDA) has reported detection of nitrosamine impurities in samples of
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         [
         <a href="#rid30">
          30,31
         </a>
         ]. Both the United States Centers for Disease Control and Prevention (CDC) and the FDA recommend that rifampin continue to be used for treatment of TB disease because the risks from TB appear to be greater than those from cancer related to nitrosamine impurities. Until these recommendations change, we favor continued use of rifampin for treatment of TB disease if acceptable to the patient, as the risk of not taking rifampin likely outweighs any potential risk from nitrosamine impurities.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Alternative agents
         </strong>
         –
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          Rifabutin
         </a>
         often is used as an alternative to
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         in patients with HIV infection on antiretroviral medications and may be used in pregnancy in consultation with an expert. Excess nitrosamine impurities have not been detected in rifabutin.
         <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">
          Rifapentine
         </a>
         should not be used in pregnancy, as there is insufficient safety information.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3170035774">
         <span class="h2">
          Monitoring during treatment
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Baseline testing
         </strong>
         – Pregnant patients and postpartum patients within three months of delivery should have baseline liver function testing (serum transaminases and bilirubin) prior to initiation of treatment for TB infection or TB disease. Additional evaluation should include testing for HIV and hepatitis B and C as well as general evaluation for chronic liver disease, alcohol use, and exposure to other hepatotoxins.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring during treatment
         </strong>
         – In the absence of evidence for underlying liver disease, initiation of antituberculous drugs should be followed by monthly evaluation for symptoms of hepatitis, clinical examination, and liver function testing. In the setting of liver disease or abnormal liver function tests, more frequent monitoring may be warranted.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient education
         </strong>
         – Patients on antituberculous drugs should be educated about the symptoms of hepatitis and instructed to stop the medication should such symptoms occur and to seek prompt evaluation of symptoms to reduce risk for progression to severe disease [
         <a href="#rid32">
          32
         </a>
         ]. Symptoms include anorexia, nausea, vomiting, dark urine, icterus, rash, persistent paresthesias of the hands and feet, persistent fatigue, weakness or fever lasting three or more days, abdominal pain (particularly right upper quadrant discomfort), easy bruising or bleeding, or arthralgias.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Regimen adjustments
         </strong>
         – Issues related to regimen adjustments and hepatotoxicity should be addressed as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection", section on 'Regimen adjustments for drug intolerance'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H387538976">
         <span class="h1">
          BREASTFEEDING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Breastfeeding may be encouraged after at least two weeks of treatment for TB disease [
         <a href="#rid24">
          24
         </a>
         ]. The small concentrations of first-line antituberculous drugs (
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         , and
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         ) in breast milk do not produce toxic effects in the nursing infant [
         <a href="#rid5">
          5,23,28,33
         </a>
         ]. Exclusively breastfed infants receiving isoniazid (either via breast milk or as directed therapy) should receive supplemental
         <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">
          pyridoxine
         </a>
         .
        </p>
        <p class="headingAnchor" id="H4092870014">
         <span class="h1">
          CONTROLLING TRANSMISSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mothers with untreated pulmonary TB disease can transmit infection to their infants. Therefore, patients with known or suspected TB disease at the time of delivery should be separated from the infant until both have been evaluated [
         <a href="#rid24">
          24
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/8007.html" rel="external">
          "Tuberculosis disease in children: Epidemiology, clinical manifestations, and diagnosis", section on 'Diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">
          "Diagnosis of pulmonary tuberculosis in adults"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If both the mother and infant have pulmonary TB disease (implying congenital TB, which is very rare), both should be started on treatment. The infant and mother need not be separated as long as both are adherent; the mother should wear a mask until no longer contagious. (See
         <a class="medical medical_review" href="/z/d/html/135189.html" rel="external">
          "Tuberculosis disease in children: Treatment and prevention"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the mother has drug-susceptible pulmonary TB disease and the infant has a positive skin test (in the absence of evidence for TB disease), the mother should be treated for TB disease and the infant should be treated for TBI. The infant and mother need not be separated as long as both are adherent; the mother should wear a mask until no longer contagious. (See
         <a class="medical medical_review" href="/z/d/html/8020.html" rel="external">
          "Tuberculosis infection (latent tuberculosis) in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the mother has drug-susceptible pulmonary TB disease and the infant has no evidence of TB infection or disease, the mother should be treated for TB disease and the infant should be treated for TB infection for three to four months. The infant and mother need not be separated as long as both are adherent; the mother should wear a mask until no longer contagious.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         After three to four months of treatment, the infant should have a repeat skin test. If the mother has drug-susceptible TB and has been adherent to treatment and has shown clinical, radiographic, and microbiologic improvement, at this point the mother should have been noncontagious (and the infant should have had no TB exposure) for at least 10 weeks:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the infant's repeat skin test is positive, the infant should be reevaluated for TB disease (see
         <a class="medical medical_review" href="/z/d/html/8020.html" rel="external">
          "Tuberculosis infection (latent tuberculosis) in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8007.html" rel="external">
          "Tuberculosis disease in children: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         ). The infant should receive a full course of treatment for either TB infection or TB disease, based on the result of the reevaluation. The infant and mother need not be separated as long as both are adherent.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the infant's repeat skin test is negative, the infant need not continue treatment for TB infection. The infant and mother need not be separated as long as the mother is adherent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the mother is still contagious, both mother and infant warrant further investigation in conjunction with expert consultation. (See
         <a class="medical medical_review" href="/z/d/html/8028.html" rel="external">
          "Treatment of drug-resistant pulmonary tuberculosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8020.html" rel="external">
          "Tuberculosis infection (latent tuberculosis) in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8007.html" rel="external">
          "Tuberculosis disease in children: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Bacille Calmette-Guérin (BCG) vaccination should not be given during pregnancy for prevention of TB since it is a live vaccine. Issues related to BCG vaccination are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/8022.html" rel="external">
          "Prevention of tuberculosis: BCG immunization and nutritional supplementation"
         </a>
         .)
        </p>
        <p>
         Issues related to controlling transmission in the setting of drug-resistant TB warrant expert consultation. General issues related to TB transmission and control are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/8000.html" rel="external">
          "Tuberculosis transmission and control in health care settings"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1394091913">
         <span class="h1">
          OUTCOMES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Outcomes for TB in pregnancy may be worse among patients with HIV infection; in one study including 80 pregnant patients with HIV and TB and 155 pregnant patients with HIV but not TB, those with TB had higher rates of preeclampsia, their infants had higher rates of mortality and low birth weight, and 12 percent of these infants were born with TB [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2786529646">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111822.html" rel="external">
          "Society guideline links: Diagnosis and treatment of tuberculosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – Pregnant patients with pulmonary tuberculosis (TB) have the same clinical manifestations as nonpregnant patients; these may include fever, cough, weight loss, night sweats, and malaise. TB in pregnant patients can present insidiously, since malaise and fatigue may be attributed to pregnancy rather than disease. In addition, it can be difficult to recognize weight loss during pregnancy. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The approach to diagnosis of TB disease in pregnant patients is the same as in nonpregnant individuals; it consists of clinical history (with epidemiologic assessment) and physical examination, followed by chest radiography (with appropriate shielding to protect the fetus). Chest imaging suggestive of pulmonary TB should prompt submission of three sputum specimens (coughed or induced) for acid-fast bacilli smear and culture as well as at least one sputum specimen for
         <em>
          Mycobacterium tuberculosis
         </em>
         nucleic acid amplification testing. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – (see
         <a class="local">
          'Clinical approach'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antituberculous regimen
         </strong>
         – We suggest that the initial regimen for treatment of TB disease in pregnancy (for presumed drug-susceptible disease) consists of
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         administered for two months, followed by isoniazid and rifampin for seven months, for a total of nine months (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Use of
         </strong>
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         <strong>
         </strong>
         – Pyrazinamide is not absolutely necessary as part of a first-line regimen and is not used routinely for treatment of pregnant patients in the United States because of limited safety data; some favor its use for patients with severe and/or extrapulmonary TB. In contrast with United States practice, pyrazinamide is recommended by the World Health Organization as part of a standard regimen for treatment of TB in pregnant patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring
         </strong>
         – Pregnant patients and postpartum patients within three months of delivery should have baseline liver function testing (serum transaminases and bilirubin) prior to initiation of treatment. In the absence of evidence for underlying liver disease, initiation of antituberculous drugs should be followed by monthly evaluation for symptoms of hepatitis, clinical examination, and liver function testing. In the setting of liver disease or abnormal liver function tests, more frequent monitoring may be warranted. (See
         <a class="local">
          'Monitoring during treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Behr MA, Kaufmann E, Duffin J, et al. Latent Tuberculosis: Two Centuries of Confusion. Am J Respir Crit Care Med 2021; 204:142.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Treatment for TB During Pregnancy. https://www.cdc.gov/tb/topic/treatment/pregnancy.htm (Accessed on August 15, 2022).
         </li>
         <li class="breakAll">
          TB Controllers. A GUIDE FOR HEALTH CARE PROVIDERS AND PUBLIC HEALTH PROGRAMS - Testing and Treatment of Latent Tuberculosis Infection in the United States: Clinical Recommendations. http://www.tbcontrollers.org/docs/resources/tb-infection/LTBI_Clinical_Recommendations_Version_002052021.pdf (Accessed on August 15, 2022).
         </li>
         <li class="breakAll">
          Clinicalinfo.hiv.gov. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines (Accessed on August 15, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. Latent TB Infection: Updated and consolidated guidelines for programmatic management, 2018. https://apps.who.int/iris/handle/10665/260233 (Accessed on March 06, 2018).
         </li>
         <li class="breakAll">
          World Health Organization. WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment. https://apps.who.int/iris/handle/10665/331170 (Accessed on August 15, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carter EJ, Mates S. Tuberculosis during pregnancy. The Rhode Island experience, 1987 to 1991. Chest 1994; 106:1466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ormerod P. Tuberculosis in pregnancy and the puerperium. Thorax 2001; 56:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knight M, Kurinczuk JJ, Nelson-Piercy C, et al. Tuberculosis in pregnancy in the UK. BJOG 2009; 116:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kothari A, Mahadevan N, Girling J. Tuberculosis and pregnancy--Results of a study in a high prevalence area in London. Eur J Obstet Gynecol Reprod Biol 2006; 126:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson EA, Thelin TJ, Dilts PV Jr. Tuberculosis complicated by pregnancy. Am J Obstet Gynecol 1973; 115:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Llewelyn M, Cropley I, Wilkinson RJ, Davidson RN. Tuberculosis diagnosed during pregnancy: a prospective study from London. Thorax 2000; 55:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Good JT Jr, Iseman MD, Davidson PT, et al. Tuberculosis in association with pregnancy. Am J Obstet Gynecol 1981; 140:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobhy S, Babiker Z, Zamora J, et al. Maternal and perinatal mortality and morbidity associated with tuberculosis during pregnancy and the postpartum period: a systematic review and meta-analysis. BJOG 2017; 124:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamadeh MA, Glassroth J. Tuberculosis and pregnancy. Chest 1992; 101:1114.
          </a>
         </li>
         <li class="breakAll">
          Starke JR. Tuberculosis in childhood and pregnancy. In: Tuberculosis: Current concepts and treatment, 2nd ed, Friedman LN (Ed), CRC Press, Boca Raton, FL 2000.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Snider DE Jr, Layde PM, Johnson MW, Lyle MA. Treatment of tuberculosis during pregnancy. Am Rev Respir Dis 1980; 122:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davidson PT. Managing tuberculosis during pregnancy. Lancet 1995; 346:199.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. Guidelines for treatment of tuberculosis, 4th edition. WHO, Geneva 2010. http://apps.who.int/iris/bitstream/10665/44165/1/9789241547833_eng.pdf?ua=1&amp;ua=1 (Accessed on October 05, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dorman SE, Nahid P, Kurbatova EV, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med 2021; 384:1705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carr W, Kurbatova E, Starks A, et al. Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:285.
          </a>
         </li>
         <li class="breakAll">
          Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk, 7th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2005.
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32 ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franks AL, Binkin NJ, Snider DE Jr, et al. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep 1989; 104:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moulding TS, Redeker AG, Kanel GC. Twenty isoniazid-associated deaths in one state. Am Rev Respir Dis 1989; 140:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Snider DE Jr, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992; 145:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000; 49:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bothamley G. Drug treatment for tuberculosis during pregnancy: safety considerations. Drug Saf 2001; 24:553.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. FDA Updates and Press Announcements on Nitrosamines in Rifampin and Rifapentine. https://www.fda.gov/drugs/drug-safety-and-availability/fda-works-mitigate-shortages-rifampin-and-rifapentine-after-manufacturers-find-nitrosamine (Accessed on October 06, 2020).
         </li>
         <li class="breakAll">
          US Food and Drug Administration. Laboratory analysis of rifampin/rifapentine products. https://www.fda.gov/drugs/drug-safety-and-availability/laboratory-analysis-rifampinrifapentine-products (Accessed on April 05, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marks SM, Mase SR, Morris SB. Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis. Clin Infect Dis 2017; 64:1670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Snider DE Jr, Powell KE. Should women taking antituberculosis drugs breast-feed? Arch Intern Med 1984; 144:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salazar-Austin N, Hoffmann J, Cohn S, et al. Poor Obstetric and Infant Outcomes in Human Immunodeficiency Virus-Infected Pregnant Women With Tuberculosis in South Africa: The Tshepiso Study. Clin Infect Dis 2018; 66:921.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 8014 Version 36.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33761302" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Latent Tuberculosis: Two Centuries of Confusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33761302" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Latent Tuberculosis: Two Centuries of Confusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33761302" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Latent Tuberculosis: Two Centuries of Confusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33761302" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Latent Tuberculosis: Two Centuries of Confusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27516382" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27516382" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27516382" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7956404" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Tuberculosis during pregnancy. The Rhode Island experience, 1987 to 1991.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11359968" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Tuberculosis in pregnancy and the puerperium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19250368" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Tuberculosis in pregnancy in the UK.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16154251" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Tuberculosis and pregnancy--Results of a study in a high prevalence area in London.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4685503" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Tuberculosis complicated by pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10639530" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Tuberculosis diagnosed during pregnancy: a prospective study from London.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7246682" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Tuberculosis in association with pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27862893" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Maternal and perinatal mortality and morbidity associated with tuberculosis during pregnancy and the postpartum period: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1555428" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Tuberculosis and pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1555428" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Tuberculosis and pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6996549" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Treatment of tuberculosis during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7616796" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Managing tuberculosis during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7616796" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Managing tuberculosis during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33951360" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35202353" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35202353" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35202353" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2495549" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Isoniazid hepatitis among pregnant and postpartum Hispanic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2782741" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Twenty isoniazid-associated deaths in one state.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1736764" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Isoniazid-associated hepatitis deaths: a review of available information.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10881762" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11444726" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Drug treatment for tuberculosis during pregnancy: safety considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11444726" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Drug treatment for tuberculosis during pregnancy: safety considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11444726" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Drug treatment for tuberculosis during pregnancy: safety considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28329197" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6367682" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Should women taking antituberculosis drugs breast-feed?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29028970" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Poor Obstetric and Infant Outcomes in Human Immunodeficiency Virus-Infected Pregnant Women With Tuberculosis in South Africa: The Tshepiso Study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
